Abeona Therapeutics DEF 14A: Executive Compensation Details
Ticker: ABEO · Form: DEF 14A · Filed: Apr 9, 2025 · CIK: 318306
| Field | Detail |
|---|---|
| Company | Abeona Therapeutics Inc. (ABEO) |
| Form Type | DEF 14A |
| Filed Date | Apr 9, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-compensation, proxy-statement, governance
Related Tickers: ABEO
TL;DR
Abeona's 2024 proxy statement is out, detailing exec pay and equity awards. Check it for compensation specifics.
AI Summary
Abeona Therapeutics Inc. filed its DEF 14A on April 9, 2025, detailing executive compensation for the fiscal year ending December 31, 2024. The filing includes information on equity awards granted, their fair value at fiscal year-end, and changes in fair value for outstanding awards. It also covers compensation details for named executive officers, including salary, bonus, and stock awards.
Why It Matters
This filing provides transparency into how Abeona Therapeutics compensates its top executives, which can influence investor perception and corporate governance.
Risk Assessment
Risk Level: medium — DEF 14A filings are routine disclosures about executive compensation and corporate governance, but can sometimes reveal information about potential shareholder concerns or changes in executive strategy.
Key Numbers
- 2024 — Fiscal Year (Reporting period for executive compensation and equity awards.)
- 2023 — Prior Fiscal Year (Used for comparative analysis of compensation and equity awards.)
Key Players & Entities
- ABEONA THERAPEUTICS INC. (company) — Filer
- 0000318306 (company) — Central Index Key
- 2024-12-31 (date) — Fiscal Year End
- 20250409 (date) — Filing Date
FAQ
What is the primary purpose of this DEF 14A filing?
The primary purpose of this DEF 14A filing is to provide detailed information regarding the compensation of Abeona Therapeutics Inc.'s named executive officers and other corporate governance matters for the fiscal year ended December 31, 2024.
When was this DEF 14A filing submitted to the SEC?
This DEF 14A filing was submitted to the SEC on April 9, 2025.
What fiscal year does the compensation information in this filing primarily cover?
The compensation information in this filing primarily covers the fiscal year ended December 31, 2024.
What is the company's Central Index Key (CIK)?
The company's Central Index Key (CIK) is 0000318306.
What industry is Abeona Therapeutics Inc. classified under?
Abeona Therapeutics Inc. is classified under the Pharmaceutical Preparations industry (SIC code 2834).
Filing Details
This Form DEF 14A (Form DEF 14A) was filed with the SEC on April 9, 2025 regarding ABEONA THERAPEUTICS INC. (ABEO).